Grace expands CDMO capacity by 25% of South Haven facility in Michigan
SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Nalu Bio, Inc., developers of a proprietary chemical synthesis platform that produces ultra-pure, high quality cannabinoids (CBD), has announced partnerships with Curia Global and Grace Fine Chemicals, two world class contract research, development and manufacturing organizations capable of scaling chemistry from the bench to commercial quantities. These partnerships will allow Nalu Bio to advance from research and development to commercial manufacturing, with supply chain excellence along the way. In addition, Nalu Bio has signed agreements with Curia Global to develop cannabinoid derivatives for therapeutic use as Active Pharmaceutical Ingredients (API) to address unmet medical needs.
LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management’s current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D’Alvise as President and Chief Executive Officer, under the oversight of Acasti’s newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and commercial presence in North Brunswick, New Jersey.
Grace Science, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GS-100, an investigational AAV9 gene replacement therapy for the treatment of NGLY1 deficiency.